TIDMCIZ
RNS Number : 5195T
Cizzle Biotechnology Holdings PLC
25 November 2021
25 November 2021
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Strategic Alliance for Early Lung Cancer Detection in China
Cizzle Biotechnology, the UK based diagnostics developer, is
pleased to announce that it has executed a Memorandum of
Understanding ("MOU") with the International Co-Innovation Centre
for Advanced Medical Technology ("iCCAMT") and Shenzhen
Intelliphecy Life Technologies Co., Ltd. ("Intelliphecy") to
develop and market the Company's proprietary early lung cancer
diagnostic tests based on the CIZ1B cancer biomarker in China.
Lung cancer is a major public health problem worldwide and
especially in China, where it is still the most common diagnosed
cancer and the leading cause of cancer related deaths. Early
detection is essential in enabling early therapeutic intervention
and improved outcomes.
iCCMAT, founded with German Medical Valley, Robert Bosch GmbH
and Sinopharm Group, aims to accelerate global med-tech innovation
in the Chinese market, by bringing together world leading
expertise. The strategic alliance is intended to accelerate product
development and clinical trials to achieve early adoption within
major cancer centers throughout China.
The MOU is non-binding, but it is intended that a full
commercial contract will be entered into in due course whereby the
parties will collaborate closely in end-to-end development,
manufacture and sale of early cancer detection products and
services. The MOU envisages that iCCAMT and Intelliphecy will fund
the activities in China and Cizzle Biotechnology will receive
payment for monoclonal antibodies and reagents produced, and
services provided, together with royalties on any sales of products
and services in China.
Initial pilots of Cizzle Biotechnology's lung cancer diagnostic
tests are planned at the Cancer Hospital Chinese Academy of Medical
Sciences, National Cancer Centre and Beijing Cancer Hospital
affiliated with Peking University.
Commenting, Allan Syms, Executive Chairman of Cizzle
Biotechnology, said:
"We are delighted to establish this important collaboration to
bring our simple blood test for the early detection of lung cancer
based on the C1Z1B biomarker to China. In 2020, nearly 715,000
deaths were caused by lung cancer in China, accounting for around
24 percent of all the three million cancer deaths* there. It is a
major health and economic challenge and together with our new
partners we aim to contribute to building effective strategies for
decreasing the cancer burden in China as part of their
comprehensive prevention and control measures."
Commenting, Dr Hui Wu, CEO and Founder of iCCAMT said:
"The C1Z1B biomarker developed by Cizzle Biotechnology has shown
promising results for lung cancer early detection in the UK. To
help the Chinese population access cost-efficient lung cancer
detection, the iCCAMT would foster this technology implementation
in China with support from its nationwide network of national
clinical centers and key opinion leaders."
Commenting, Dr Xiaoyun Huang, CEO and Founder of Intelliphecy said:
"The ability to detect lung cancer at an early stage is key for
the improvement of patient survival and can eventually reduce the
medical burden of lung cancer. We are excited to enter into
partnership with Cizzle Biotechnology and iCCAMT to develop an
early lung cancer diagnostic test based on Cizzle's proprietary
technology with the CIZ1B cancer biomarker. We are looking forward
to reaching important milestones together with our partners in the
near future."
*https://www.statista.com/statistics/1053667/china-cancer-death-number-by-type/
This announcement contains inside information for the purposes
of article 7 of EU Regulation 596/2014 which forms part of domestic
UK law pursuant to the European Union (Withdrawal) Act 2018 ("UK
MAR") . Upon the publication of this announcement this inside
information is now considered to be within the public domain.
Enquiries:
Cizzle Biotechnology Holdings Via IFC Advisory
plc
Allan Syms (Executive Chairman)
Allenby Capital Limited +44(0) 20 33285656
John Depasquale
Alex Brearley
Novum Securities Limited +44(0) 20 7399 9400
Colin Rowbury
Jon Bellis
IFC Advisory Limited +44(0) 20 3934 6630
Tim Metcalfe
Florence Chandler
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early
detection of lung cancer. Cizzle Biotechnology is a spin- out from
the University of York, founded in 2006 around the work of
Professor Coverley and colleagues . Its proof-of-concept prototype
test is based on the ability to detect a stable plasma biomarker, a
variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell
nuclear protein involved in DNA replication, and the targeted CIZ1B
variant is highly correlated with early stage lung cancer.
For more information, please see
https://cizzlebiotechnology.com
You can also follow the Company through its twitter account
@CizzlePlc and on LinkedIn.
About International Co-Innovation Centre for Advanced Medical
Technology ("iCCAMT")
iCCAMT , founded with German Medical Valley, Robert Bosch GmbH,
Sinopharm Group, aim s to accelerate global healthcare innovation
in China. iCCAMT is dedicated to support innovative healthcare SMEs
(small and medium sized companies) to grow in China and promote
technology transfer. With global health technology network and
supports from industry giants, iCCAMT has developed comprehensive
platforms to strengthen cross-border health technology
collaborations, and help global health technology companies enter
the China market.
For more information, please see http://www.iccamt.com
About Shenzhen Intelliphecy Life Technologies Co., Ltd.
("Intelliphecy")
Intelliphecy is aiming to innovate technologies in the hope to
win the war against cancer, aspiring to out-smart cancer cells with
an intelligent prophecy. At the core of Intelliphecy's technology
portfolio lies artificial intelligence driven big data analytics,
which is devoted to predictive modeling of cancer hallmarks using
quantitative information. Its research and development is grounded
in both identification of cancer at early stage and prediction of
optimal treatment strategies for individual cancer patients.
Intelliphecy has established research collaborations with major
cancer centres throughout China.
For more information, please see http://www.intelliphecy.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALLEAPFLALAFFFA
(END) Dow Jones Newswires
November 25, 2021 01:59 ET (06:59 GMT)
Cizzle Biotechnology (LSE:CIZ)
Historical Stock Chart
From Apr 2024 to May 2024
Cizzle Biotechnology (LSE:CIZ)
Historical Stock Chart
From May 2023 to May 2024